ECOG-ACRIN E1910: A phase III trial of blinatumomab plus chemotherapy vs chemotherapy alone in patients with newly diagnosed BCR::ABL1-negative B-ALL

The phase III ECOG-ACRIN E1910 trial (NCT02003222) demonstrated that adding blinatumomab to consolidation chemotherapy significantly improved 3-year overall survival (85% vs 68%) and improved relapse-free survival (80% vs 64%) compared with chemotherapy alone in patients aged 30–70 years with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in MRD-negative remission. With a median follow-up of 43 months, the combination therapy showed a higher incidence of Grade 3 non-hematologic adverse events and treatment-related psychiatric or neurological events (43% vs 36% and 23% vs 5%, respectively). 

These results led to FDA (2024) and EC (2025) approvals of blinatumomab as consolidation therapy for CD19+ Ph- B-ALL, regardless of MRD status. The findings support the inclusion of immunotherapy in initial treatment for B-ALL, changing the frontline standard of care for patients with ALL.

This educational resource is independently supported by Amgen. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.